Results 11 to 20 of about 3,065,291 (226)

Chinese Prostate Cancer Consortium (CPCC) Chinese expert consensus on advanced prostate cancer: clinical management of patients with metastatic hormone-sensitive prostate cancer treated by initial novel hormone therapy (2022 edition) [PDF]

Zhongguo aizheng zazhi, 2022
Metastatic hormone-sensitive prostate cancer (mHSPC) is a male health concern requiring continuous attention. In 2021, an important update was included in domestic and international guidelines regarding the recommendations of initial systemic therapy for
Chinese Prostate Cancer Consortium (CPCC), YE Dingwei, HUANG Jian
doaj   +3 more sources

Molecular Profiling of Prostate Cancer Patients [PDF]

, 2009
In the UK, more than 30 000 men are diagnosed annually with prostate cancer (PCa) and about 10 000 men die from it each year. Although several molecular markers have been associated with prostate cancer development and/ or progression, only few of them
Nna, Emmanuel Okechukwu
core   +7 more sources

Tyrol Prostate Cancer Demonstration Project : early detection, treatment, outcome, incidence and mortality [PDF]

, 2008
This study aimed to evaluate the effectiveness of a well-controlled programme of early detection and treatment of prostate cancer in the population of Tyrol, Austria, where such a programme of early detection and treatment was initiated in 1988 and where
Severi, Gianluca, Frauscher, Ferdinand, Horninger, Wolfgang, Klocker, Helmut, Schennach, Harald, Tyrol Prostate Canc Screening Grp, Boniol, Mathieu, , Tyrol Prostate Canc Screening Grp, Bektic, Jasmin, Boyle, Peter, Robertson, Chris, Pelzer, Alexandre, Oberaigner, Wilhelm, Schafer, Georg, Bartsch, Georg   +14 more
core   +4 more sources

Examining the influence of illness perception and financial toxicity on the quality of life of prostate cancer patients

African Journal of Urology, 2021
Background Cancer of the prostate (CaP) is a public health problem that affects the male genitourinary system causing a significant threat to men’s quality of life (QoL).
Elizabeth O. Akin-Odanye, Chidiebere N. Ogo, Faoziyat A. Sulaiman, Lawal Suleiman, Motolani E. Ogunsanya, Folakemi T. Odedina   +5 more
doaj   +1 more source

Gene amplifications associated with the development of hormone- resistant prostate cancer [PDF]

, 2003
Purpose: Hormone resistance remains a significant clinical problem in prostate cancer with few therapeutic options. Research into mechanisms of hormone resistance is essential.
Krishnan, S., Witton, C.J., Edwards, J., Bartlett, J.M.S.   +3 more
core   +8 more sources

Prostate cancer

Salud Pública de México, 2016
Prostate cancer is the most frequent tumor found in men worldwide and in Mexico in particular. Age and family history are the main risk factors. The diagnosis is made by prostate biopsy in patients with abnormalities detected in their prostate-specific antigen (PSA) levels or digital rectal exam (DRE).
Ricardo Alonso Castillejos-Molina, Fernando Bernardo Gabilondo-Navarro   +1 more
  +8 more sources

The relationship between biochemical recurrence and number of lymph nodes removed during surgery for localized prostate cancer

BMC Urology, 2023
Purpose To assess whether completeness of pelvic lymph node dissection (PLND) as measured by lymph node yield reduces biochemical recurrence (BCR) in men undergoing radical prostatectomy (RP) for prostate cancer (PCa), stratified according to Briganti ...
Paul Doan, Athos Katelaris, Matthijs J. Scheltema, Andrew Hayen, Amer Amin, Amila Siriwardana, Minh Tran, Bart Geboers, William Gondoputro, Anne Maree Haynes, Jayne Matthews, Warick Delprado, Phillip D. Stricker, James Thompson   +13 more
doaj   +1 more source

Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen

The World Journal of Men's Health, 2023
Purpose: Prostate cancer (PCa) screening can lead to potential over-diagnosis/over-treatment of indolent cancers. There is a need to optimize practices to better risk-stratify patients.
Zoe D. Michael, Srinath Kotamarti, Rohith Arcot, Kostantinos Morris, Anand Shah, John Anderson, Andrew J. Armstrong, Rajan T. Gupta, Steven Patierno, Nadine J. Barrett, Daniel J. George, Glenn M. Preminger, Judd W. Moul, Kevin C. Oeffinger, Kevin Shah, Thomas J. Polascik   +15 more
doaj   +1 more source

Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes

BMC Urology, 2022
Background To report the feasibility, oncological and functional outcomes of salvage robot-assisted radical prostatectomy (sRARP) for recurrent prostate cancer (PCa) after irreversible electroporation (IRE).
Alexandar Blazevski, William Gondoputro, Matthijs J. Scheltema, Amer Amin, Bart Geboers, Daniela Barreto, Anne-Maree Haynes, Ron Shnier, Warick Delprado, Shikha Agrawal, James E. Thompson, Phillip D. Stricker   +11 more
doaj   +1 more source

Circulating microRNAs as potential new biomarkers for prostate cancer [PDF]

, 2013
Since they were first described in the 1990s, circulating microRNAs (miRNAs) have provided an active and rapidly evolving area of current research that has the potential to transform cancer diagnostics and therapeutics.
Bevan, C. L., J Waxman, Waxman, J, Dart, Dafydd Alwyn, A Sita-Lumsden, Waxman, J., Sita-Lumsden, A., C L Bevan, Dart, DA, Sita-Lumsden, A, Bevan, CL, D A Dart   +11 more
core   +1 more source